|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
AU665207B2
(en)
|
1991-07-29 |
1995-12-21 |
Warner-Lambert Company |
Quinazoline derivatives as acetylcholinesterase inhibitors
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
WO1998030243A1
(en)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
US6569897B1
(en)
|
1998-01-16 |
2003-05-27 |
Purdue Research Foundation |
Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
|
|
BR9907300A
(pt)
|
1998-01-27 |
2000-10-24 |
Aventis Pharm Prod Inc |
Inibidores do fator xa oxoaza-heterociclila substituìdos
|
|
JP2003529531A
(ja)
|
1998-11-25 |
2003-10-07 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換オキソアザへテロシクリルＸａ因子阻害剤
|
|
SK1182002A3
(en)
|
1999-07-28 |
2002-11-06 |
Aventis Pharm Prod Inc |
Substituted oxoazaheterocyclyl compounds
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
JP2004502655A
(ja)
|
2000-06-30 |
2004-01-29 |
イーライ・リリー・アンド・カンパニー |
精神病の処置のための組み合わせ療法
|
|
AU2002245692A1
(en)
|
2001-03-15 |
2002-10-03 |
David Pharmaceuticals |
Methods for restoring cognitive function following systemic stress
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
UA79940C2
(en)
|
2001-11-26 |
2007-08-10 |
Cortex Pharma Inc |
Carbonylbenzoxazine compounds for enhancing of glutamatergic synaptic responses
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
US20060233843A1
(en)
|
2003-02-19 |
2006-10-19 |
Conn P J |
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
|
|
RU2358735C2
(ru)
|
2003-03-28 |
2009-06-20 |
Акадиа Фармасьютикалз Инк. |
Агонисты м1 мускариновых рецепторов для противоболевой терапии
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
JP2008537961A
(ja)
|
2005-04-15 |
2008-10-02 |
ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ |
Ｇｐｃｒモジュレーター
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
MY159523A
(en)
|
2005-12-21 |
2017-01-13 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
ES2374995T3
(es)
|
2007-01-03 |
2012-02-23 |
Les Laboratoires Servier |
Compuesto de [1,2,3]-benzotriazinona 3-sustituido para mejorar las respuestas sinápticas glutamatérgicas.
|
|
WO2008113072A2
(en)
|
2007-03-15 |
2008-09-18 |
Board Of Regents, The University Of Texas System |
Gpcr enhanced neuroprotection to treat brain injury
|
|
CA2697454C
(en)
|
2007-08-29 |
2015-11-03 |
Schering Corporation |
2-carboxy substituted indole derivatives and methods of use thereof
|
|
TW200924751A
(en)
|
2007-08-29 |
2009-06-16 |
Schering Corp |
2,3-substituted indole derivatives and methods of use thereof
|
|
MX2010002318A
(es)
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
|
|
HUE037639T2
(hu)
|
2007-09-21 |
2018-09-28 |
Acadia Pharm Inc |
Pimavanszerin együttes beadása más szerekkel
|
|
CA2700332A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
US8765757B2
(en)
|
2007-11-16 |
2014-07-01 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
CA2705587A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
PE20120031A1
(es)
|
2008-11-20 |
2012-02-05 |
Merck Sharp & Dohme |
Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
|
|
EP2398324B1
(en)
|
2009-02-23 |
2014-09-03 |
Merck Sharp & Dohme Corp. |
PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
|
|
EP2403340A4
(en)
|
2009-03-05 |
2012-10-31 |
Mithridion Inc |
COMPOUNDS AND COMPOSITIONS FOR IMPROVED PERCEPTION, MANUFACTURING METHOD AND TREATMENT PROCESS
|
|
EP2421366B1
(en)
|
2009-04-20 |
2013-08-28 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
EP3061821B1
(en)
|
2009-07-22 |
2019-07-10 |
Puretech Health LLC |
Compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
BR112012003464B8
(pt)
|
2009-08-31 |
2021-05-25 |
Merck Sharp & Dohme |
compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
|
|
US8895580B2
(en)
|
2009-10-21 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone M1 receptor positive allosteric modulators
|
|
EP2512245B1
(en)
|
2009-12-14 |
2014-07-23 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone m1 receptor positive allosteric modulators
|
|
US8383638B2
(en)
|
2009-12-21 |
2013-02-26 |
Merck Sharp & Dohme |
Aminobenzoquinazolinone M1 receptor positive allosteric modulators
|
|
EP2582241B1
(en)
*
|
2010-06-15 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
|
|
WO2012003147A1
(en)
|
2010-07-01 |
2012-01-05 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
WO2012047702A1
(en)
*
|
2010-10-04 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2012149524A1
(en)
|
2011-04-29 |
2012-11-01 |
The University Of Toledo |
Muscarinic agonists as enhancers of working memory and cognitive flexibility
|
|
WO2012158473A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
WO2013129622A1
(ja)
|
2012-03-02 |
2013-09-06 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
KR102109992B1
(ko)
|
2012-03-23 |
2020-05-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
JP6211530B2
(ja)
|
2012-11-19 |
2017-10-11 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
RU2642779C2
(ru)
|
2012-12-27 |
2018-01-26 |
Ф.Хоффманн-Ля Рош Аг |
Ингибиторы сомт
|
|
WO2014117920A1
(en)
|
2013-02-04 |
2014-08-07 |
Merck Patent Gmbh |
Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
|
|
US10738024B2
(en)
|
2013-05-06 |
2020-08-11 |
Indiana University Research And Technology Corporation |
Compounds for treatment of angiogenesis-mediated diseases
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
MY195742A
(en)
|
2014-04-23 |
2023-02-08 |
Takeda Pharmaceuticals Co |
Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease
|
|
EP3144308B1
(en)
|
2014-05-16 |
2020-06-24 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
WO2015190564A1
(ja)
|
2014-06-13 |
2015-12-17 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
CA2988572A1
(en)
*
|
2015-06-26 |
2016-12-29 |
Takeda Pharmaceutical Company Limited |
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
|
|
WO2017044693A1
(en)
|
2015-09-11 |
2017-03-16 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
EP3366679B1
(en)
|
2015-10-20 |
2021-03-24 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
JP6860551B2
(ja)
|
2016-03-11 |
2021-04-14 |
武田薬品工業株式会社 |
芳香環化合物
|
|
WO2018122845A1
(en)
|
2016-12-29 |
2018-07-05 |
Rvx Therapeutics Ltd. |
Methods and compositions for potentiating cns drugs and reducing their side effects
|